209 related articles for article (PubMed ID: 31510952)
1. Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.
Takashima Y; Yoshimura T; Kano Y; Hayano A; Hondoh H; Ikenaka K; Yamanaka R
BMC Cancer; 2019 Sep; 19(1):910. PubMed ID: 31510952
[TBL] [Abstract][Full Text] [Related]
2. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
Hayano A; Takashima Y; Yamanaka R
Int J Clin Oncol; 2019 Sep; 24(9):1020-1029. PubMed ID: 30993483
[TBL] [Abstract][Full Text] [Related]
3. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.
Takashima Y; Hamano M; Fukai J; Iwadate Y; Kajiwara K; Kobayashi T; Hondoh H; Yamanaka R
Sci Rep; 2020 May; 10(1):8435. PubMed ID: 32439996
[TBL] [Abstract][Full Text] [Related]
4. Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells.
Takashima Y; Hayano A; Yamanaka R
Clin Cancer Res; 2020 Jun; 26(11):2754-2766. PubMed ID: 32108030
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
6. Gene expression and angiotropism in primary CNS lymphoma.
Rubenstein JL; Fridlyand J; Shen A; Aldape K; Ginzinger D; Batchelor T; Treseler P; Berger M; McDermott M; Prados M; Karch J; Okada C; Hyun W; Parikh S; Haqq C; Shuman M
Blood; 2006 May; 107(9):3716-23. PubMed ID: 16418334
[TBL] [Abstract][Full Text] [Related]
7. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
9. Sialylated N-glycans in adult rat brain tissue--a widespread distribution of disialylated antennae in complex and hybrid structures.
Zamze S; Harvey DJ; Chen YJ; Guile GR; Dwek RA; Wing DR
Eur J Biochem; 1998 Nov; 258(1):243-70. PubMed ID: 9851715
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
11. The Effect of a New Glucose-Methotrexate Conjugate on Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma Cell Lines.
Woźniak M; Makuch S; Pastuch-Gawołek G; Wiśniewski J; Szeja W; Nowak M; Krawczyk M; Agrawal S
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925555
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
13. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
Joerger M; Huitema AD; Illerhaus G; Ferreri AJ
Leuk Lymphoma; 2012 Oct; 53(10):1867-75. PubMed ID: 22530664
[TBL] [Abstract][Full Text] [Related]
14. Determination of major sialylated N-glycans and identification of branched sialylated N-glycans that dynamically change their content during development in the mouse cerebral cortex.
Torii T; Yoshimura T; Narumi M; Hitoshi S; Takaki Y; Tsuji S; Ikenaka K
Glycoconj J; 2014 Dec; 31(9):671-83. PubMed ID: 25417067
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation of a CNS-specific extracellular matrix glycoprotein, tenascin-R, is dominated by O-linked sialylated glycans and "brain-type" neutral N-glycans.
Zamze S; Harvey DJ; Pesheva P; Mattu TS; Schachner M; Dwek RA; Wing DR
Glycobiology; 1999 Aug; 9(8):823-31. PubMed ID: 10406848
[TBL] [Abstract][Full Text] [Related]
16. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
17. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system.
Deckert-Schlüter M; Rang A; Wiestler OD
Acta Neuropathol; 1998 Aug; 96(2):157-62. PubMed ID: 9705131
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
Bokstein F; Lossos A; Lossos IS; Siegal T
Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma with testicular relapse.
Harney J; Pope A; Short SC
Clin Oncol (R Coll Radiol); 2004 May; 16(3):193-5. PubMed ID: 15191006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
